ASH 2019 | CARTITUDE-1 results: CAR-T against BCMA in R/R MM
Deepu Madduri
• 9 Dec 2019
Deepu Madduri, MD, Icahn School of Medicine at Mount Sinai, New York, NY, discusses the Phase Ib results from the ongoing CARTITUDE-1 study with ciltacabtagene autoleucel (cilta-cel; formerly JNJ-4528, a CAR-T cell therapy containing two BCMA-targeting single-domain antibodies (NCT03548207). This CAR T-cell therapy delivered early and deep responses, including measurable residual disease (MRD) negativity, with a manageable safety profile in patients with relapsed and/or refractory multiple myeloma (MM). This press briefing was recorded at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.
